• 21610 Citations
  • 61 h-Index
19982019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Dong-Wan Kim is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 30 Similar Profiles
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
Survival Medicine & Life Sciences
Mutation Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2019

  • 21610 Citations
  • 61 h-Index
  • 265 Article
  • 5 Review article
  • 2 Comment/debate
  • 2 Letter
Non-Small Cell Lung Carcinoma
Drug Therapy
Disease-Free Survival
Cell Death
Confidence Intervals

Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial

Kim, D-W., Lee, D. H., Han, J. Y., Lee, J., Cho, B. C., Kang, J. H., Lee, K. H., Cho, E. K., Kim, J. S., Min, Y. J., Cho, J. Y., An, H. J., Kim, H. G., Lee, K. H., Kim, B. S., Jang, I. J., Yoon, S., Han, O. P., Noh, Y. S., Hong, K. Y. & 1 others, Park, K., 1 Sep 2019, In : Lung Cancer. 135, p. 66-72 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Safety
Mutation
Neoplasms

Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer

Choi, M., Keam, B., Ock, C. Y., Kim, M. S., Kim, T. M., Kim, D-W. & Heo, D. S., 1 Jul 2019, In : Clinical Lung Cancer. 20, 4, p. e442-e451

Research output: Contribution to journalArticleResearchpeer-review

Pemetrexed
Lung Neoplasms
Neoplasm Metastasis
Non-Small Cell Lung Carcinoma
Therapeutics
2 Citations (Scopus)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

Schuler, M., Tan, E. H., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C. H., Lee, K. H., Lu, S., Shi, Y., Kim, S. W., Laskin, J., Kim, D-W., Arvis, C. D., Kölbeck, K., Massey, D., Märten, A., Paz-Ares, L. & Park, K., 1 Jun 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 6, p. 1569-1579 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Lung
Mutation
Therapeutics
Disease-Free Survival
BIBW 2992
3 Citations (Scopus)

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1–Expressing NSCLC

Barlesi, F., Garon, E. B., Kim, D-W., Felip, E., Han, J. Y., Kim, J. H., Ahn, M. J., Fidler, M. J., Gubens, M. A., de Castro, G., Surmont, V., Li, Q., Deitz, A. C., Lubiniecki, G. M. & Herbst, R. S., 1 May 2019, In : Journal of Thoracic Oncology. 14, 5, p. 793-801 9 p.

Research output: Contribution to journalArticleResearchpeer-review

docetaxel
Quality of Life
Ligands
Health Status
Neoplasms